BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/4/2016 5:58:00 PM | Browse: 1033 | Download: 1420
 |
Received |
|
2016-03-25 14:55 |
 |
Peer-Review Started |
|
2016-03-25 16:12 |
 |
To Make the First Decision |
|
2016-05-12 14:34 |
 |
Return for Revision |
|
2016-05-12 15:48 |
 |
Revised |
|
2016-05-27 21:31 |
 |
Second Decision |
|
2016-06-28 09:08 |
 |
Accepted by Journal Editor-in-Chief |
|
2016-06-28 15:02 |
 |
Accepted by Executive Editor-in-Chief |
|
2016-07-06 18:25 |
 |
Articles in Press |
|
2016-07-06 18:25 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-07-26 14:47 |
 |
Publish the Manuscript Online |
|
2016-08-04 17:58 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Systematic Reviews |
Article Title |
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
|
Manuscript Source |
Invited Manuscript |
All Author List |
Cristiana Lo Nigro, Vincenzo Ricci, Daniela Vivenza, Cristina Granetto, Teresa Fabozzi, Emanuela Miraglio and Marco C Merlano |
Funding Agency and Grant Number |
|
Corresponding Author |
Cristiana Lo Nigro, PhD, Laboratory of Cancer Genetics and Translational Oncology, Department of Oncology, S. Croce and Carle Teaching Hospital, via Carle 25, 12100 Cuneo, Italy. lonigro.c@ospedale.cuneo.it |
Key Words |
Metastatic colorectal cancer; Anti-epidermal growth factor receptor therapy; KRAS; Biomarkers; Antibody-dependent cell-mediated cytotoxicity |
Core Tip |
This review focuses on progress in the metastatic colorectal cancer (mCRC) personalized treatment and on the role of prognostic and predictive biomarkers available for selecting patients treated with anti-epidermal growth factor receptor (EGFR) therapy. Not only the KRAS mutational status but also BRAF, NRAS, PIK3CA, TP53 and PTEN alterations might be useful in selecting patients who likely will respond to anti-EGFR treatments. In particular, we focused on the following points: (1) predictive biomarkers of response to anti-EGFR therapy; (2) prognostic biomarkers; and (3) new prognostic value of antibody-dependent cell-mediated cytotoxicity activity induced by cetuximab in mCRC. |
Publish Date |
2016-08-04 17:58 |
Citation |
Lo Nigro C, Ricci V, Vivenza D, Granetto C, Fabozzi T, Miraglio E, Merlano MC. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol 2016; 22(30): 6944-6954 |
URL |
http://www.wjgnet.com/1007-9327/full/v22/i30/6944.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v22.i30.6944 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345